Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645545 | 0.91 | PDE2A (0.42) | NR1H4PDE2APPARGALDH1A1LMNA | |
| SCHEMBL1643047 | 0.86 | NR1H4 (0.41) | NR1H4PDE2AALDH1A1LMNAROCK2 | |
| SCHEMBL1644700 | 0.86 | HPGDS (0.42) | NR1H4PDE2AALDH1A1LMNAROCK2 | |
| SCHEMBL1284683 | 0.84 | NR1H4 (0.47) | NR1H4 | |
| SCHEMBL1643203 | 0.84 | LMNA (0.41) | NR1H4ALDH1A1LMNAROCK2ROCK1 | |
| SCHEMBL1643131 | 0.84 | PDE2A (0.45) | NR1H4PDE2A | |
| SCHEMBL1644460 | 0.83 | NR1H4 (0.38) | NR1H4PDE2APPARGALDH1A1LMNA | |
| SCHEMBL1643125 | 0.83 | CYP17A1 (0.40) | NR1H4PDE2APPARGLMNAROCK2 | |
| SCHEMBL1643554 | 0.82 | NR1H4 (0.40) | NR1H4PDE2APPARGALDH1A1ROCK2 | |
| SCHEMBL1644603 | 0.80 | MEN1 (0.37) | PDE2AALDH1A1LMNAROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | NR1H4 732/4885PDE2A 1116/4885PPARG 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.